Jossan S S, Ekblom J, Gudjonsson O, Hagbarth K E, Aquilonius S M
Department of Medical Pharmacology, Uppsala University, Sweden.
J Neural Transm Suppl. 1994;41:237-41. doi: 10.1007/978-3-7091-9324-2_30.
In this paper we present results from a double blind cross over trial with deprenyl, a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor, in 10 patients suffering from amyotrophic lateral sclerosis. The patients were randomised in such a way that half of the patients started with the active drug and half with the placebo treatment. Each patient was given 10 mg deprenyl (eldepryl, 10 mg tablets) per day for 12 weeks and then placebo for the same length of time. There was a drug free period of 12 weeks between the courses. The neurological status of the patients were evaluated every six weeks by using Norris, spinal and bulbar scores and it was observed that all cases deteriorated in their clinical status during the 36 weeks of the controlled study. MAO-B activity in blood platelets was completely inhibited during treatment with deprenyl. In the preliminary analysis performed so far, no obvious retardation in the progress of the disease could be observed with deprenyl treatment.
在本文中，我们展示了一项针对10例肌萎缩侧索硬化症患者进行的双盲交叉试验结果，该试验使用了司来吉兰，一种选择性且不可逆的单胺氧化酶-B（MAO-B）抑制剂。患者被随机分组，使得一半患者从活性药物开始治疗，另一半从安慰剂治疗开始。每位患者每天服用10毫克司来吉兰（思吉宁，10毫克片剂），持续12周，然后服用相同时长的安慰剂。两个疗程之间有12周的停药期。每六周使用诺里斯、脊髓和延髓评分对患者的神经状态进行评估，结果观察到在对照研究的36周期间，所有病例的临床状态均恶化。在用司来吉兰治疗期间，血小板中的MAO-B活性被完全抑制。在目前进行的初步分析中，未观察到司来吉兰治疗能明显延缓疾病进展。
